Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting

Journal of the Medical Association of Thailand

Volumn 88, Issue 12, 2005, Pages 1790-1796

  Voravud, Narin ^a   Sriuranpong, Viroj ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Cisplatin induced emesis; Dexamethasone; Ramosetron

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; RAMOSETRON;

ACUTE DISEASE; ADULT; AGED; ANTIEMETIC ACTIVITY; ARTICLE; BLURRED VISION; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; FEMALE; FLUSHING; FREQUENCY ANALYSIS; HAND PARESTHESIA; HICCUP; HUMAN; HYPOGLYCEMIA; LEG EDEMA; LIVER CANCER; LUNG CANCER; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PROPHYLAXIS; PRURITUS; RETCHING; SIDE EFFECT; THROMBOCYTOSIS; TONGUE CANCER; UTERINE CERVIX CANCER;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CISPLATIN; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; VOMITING;

EID: 33244466064     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Jantunen IT, Kataaja VV, Mahonen TT. An overview of randomized studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer 1997; 33: 66-74.
2. Noda K, Ikeda M, Yoshida O, Yano S, Taguchi T, Shimoyama T, et al. Clinical evaluation of YM060 in the treatment of nausea and vomiting induced by anticancer drugs: a phase-II dose finding study. Jpn J Clin Exp Med 1994; 71: 2753-64.
3. Noda K, Ikeda M, Yoshida O, Yano S, Taguchi T, Shimoyama T, et al. Clinical evaluation of the YM060 injection for nausea or vomiting induced by cisplatin, an antineoplastic agent: a single blind group comparative study with granisetron as the control (in Japanese). J New Remed Clin 1994; 43: 2241-55.
4. Roila F, Tnato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9: 675-8.
5. Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ, et al. A randomized double blind comparison of intravenous ondansetron lone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994; 12: 596-600.
6. Latreille J, Stewart D, Laberge F, Hoskins P, Rusthoven J, McMurtrie E, et al. Dexamethasone improves the efficacy of granisetron in the first 24 hours following high-dose cisplatin chemotherapy. Support Care Cancer 1995; 3: 307-12.
7. Heron JF, Goedhals L, Jordaan JP, Cunningham J, Cedar E. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. Ann Oncol 1994; 5: 579-84.
8. Hulstaert F, Van Belle S, Bleiberg H, Canon JL, Dewitte M, Buyse M, et al. Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy induced nausea and vomiting. J Clin Oncol 1994; 12: 2439-46.
9. Villalon A, Chan V. Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis. Support Care Cancer 2004; 12: 58-63.